Concord Biotech Ltd

Concord Biotech announced the successful conclusion of a USFDA inspection at its Unit II formulation facility in Valthera, Gujarat. The inspection resulted in a single minor procedural observation, which is not related to Good Manufacturing Practices (GMP). The company will submit a comprehensive response to this observation within the stipulated timeline. Concord Biotech does not anticipate any material impact on its current business operations or existing supplies from this facility due to this development. The USFDA has issued one minor observation which is procedural in nature and not related to GMP.

Concord Biotech Limited announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors, following a review by the Audit Committee, approved these results. The company submitted the results along with a Limited Review Report from its statutory auditors, BSR & Co. LLP, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board meeting commenced at 3:30 PM and concluded at 4:35 PM on July 31, 2026. The limited review report indicates no material misstatements were found in the accompanying financial statements.

Concord Biotech opened FY27 with a clear rebound after a soft FY26. Q1 consolidated revenue from operations rose 26.2% YoY to ₹257.5 Cr and net profit (attributable to owners) rose ~33% to ₹58.5 Cr (₹57.7 Cr PAT for the period after a ₹0.8 Cr non-controlling loss), against ₹204.0 Cr and ₹44.1 Cr a year ago. Margins moved the right way on both lines: operating margin expanded to ~32.0% from 30.1%, and net margin to ~22.7% from 20.2%, with the print carrying no exceptional items this quarter — so the reported growth is the underlying growth, not an optics effect. EPS was ₹5.52 vs ₹4.21. The result validates management's own guidance from the Q3 FY26 concall, where it flagged FY26 as below historical averages but guided FY27 back toward historical growth with potential acceleration to a ~25% CAGR as the injectable facility, CDMO partnerships and new launches scale. A 26% YoY topline in the very first quarter sits squarely on that path. The margin recovery also aligns with management's claim that core business margins remain stable (~40% at the core level) even as new ventures carry start-up costs — the consolidated drag from those ventures is visible in the standalone-vs-consolidated gap: standalone PAT grew 43.8% YoY (to ₹61.2 Cr) versus 31% consolidated, because loss-making subsidiaries (Celliimune, acquired Apr 2, 2026; Stellon Biotech) dilute the group number. Readers seeing the higher standalone figure elsewhere should treat consolidated as the true group picture. Against the sequential quarter, revenue fell 21% and PAT 35% versus Q4 FY26 (₹326 Cr / ₹88.5 Cr), but Q4 is seasonally Concord's strongest quarter and that step-down is a seasonality artifact, not a deterioration — the YoY comparison is the signal here. Concurrent developments support the recovery read: Unit-II cleared Kenya and Uganda regulatory inspections in June, and the board declared the quarter alongside a final dividend (July 24 record date) and the 41st AGM. No formal quarterly guidance or published street consensus was available for this print; the FY26 base had seen consolidated revenue decline ~12%, so this quarter is the first concrete evidence of the guided turnaround taking hold. Management will detail the recovery on its August 3 earnings call.

Concord Biotech Ltd has scheduled a Board of Directors meeting for July 31, 2026. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, along with the limited review report from the statutory auditors. Additionally, the company confirmed that the trading window for dealing in its securities will remain closed until 48 hours after the declaration of these financial results, in compliance with SEBI regulations and the company's code of conduct regarding insider trading.

Concord Biotech Limited has announced that its 41st Annual General Meeting (AGM) will be held on Friday, July 31, 2026, via Video Conferencing. The company has fixed Friday, July 24, 2026, as the record date for determining shareholders' entitlement to the final dividend for the financial year ended March 31, 2026. The register of members and share transfer books will be closed from Saturday, July 25, 2026, to Friday, July 31, 2026, inclusive. The dividend payment, if approved at the AGM, will be distributed by August 30, 2026, subject to tax deductions.

Concord Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as mandated by SEBI regulations. The report, which is part of the company's 41st Annual Report, details its operations, products, and employee data. The company's business activities primarily involve the manufacturing of pharmaceuticals, with 78.6% of turnover from Active Pharmaceutical Ingredients (APIs) and 21.4% from finished formulations. Concord serves over 300 customers in more than 70 countries, with exports contributing 46.56% to its total turnover. The report also includes details on its standalone reporting basis, reasonable assurance from its assurance provider, and contact information for queries.

Concord Biotech Limited has submitted its Annual Report for the financial year 2025-26, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report details the company's performance, corporate overview, financial statements, and management reports. It emphasizes the company's commitment to creating enduring value through innovation, operational excellence, and sustainable practices. The report covers various aspects of the company's operations, including its strategic blueprint, risk management, and value creation model across intellectual, manufactured, financial, human, natural, and social capital. It also includes the Director's Report, Corporate Governance Report, Business Responsibility & Sustainability Report, and Management Discussion & Analysis.

Concord Biotech Ltd has announced its 41st Annual General Meeting (AGM) will be held on Friday, July 31, 2026, at 12:00 Noon via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting will address ordinary business including the adoption of audited standalone and consolidated financial statements for FY 2025-26, declaration of a dividend of ₹7.55 per equity share (755%), and the re-appointment of Mr. Ankur Vaid as a director. Special business includes the appointment of Mrs. Ekta Gupta as an Independent Director. The cut-off date for voting rights and dividend entitlement is fixed as Friday, July 24, 2026.

Concord Biotech Ltd announced the successful completion of inspections by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. The inspections, conducted from June 18 to June 24, 2026, concluded successfully. This milestone is expected to strengthen Concord Biotech's global manufacturing and regulatory footprint, reinforcing its commitment to high quality and regulatory standards as part of its international growth strategy.

Concord Biotech Ltd has entered into an agreement to invest in FSGE Renewable Power Private Limited for a Wind Solar Hybrid Power Project in Gujarat. The investment involves acquiring 27.38% equity share capital in FSGE, which is setting up a 6.3 MW AC Wind and 6.3 MWp DC Solar capacity project for Concord's Limbasi Facility. This strategic move aligns with Concord's commitment to sustainability, reducing its carbon footprint, and achieving long-term financial benefits through lower energy costs. FSGE is yet to commence commercial operations, and upon acquisition, it will become an associate of Concord Biotech. The transaction is considered a Related Party Transaction but will be conducted on an arm's length basis.